



PHARMACEUTICALS EXPORT PROMOTION COUNCIL

(Set up by Ministry of Commerce, Govt. of India)

COPY

Date : 04-06-2010

News / Story reproduced with thanks:- RTT News

Aurobindo Pharma Receives US FDA Approval for Ceftazidime For Injection

Direct link to the News/Story:-

<http://www.rttnews.com/Content/IndianNews.aspx?Id=1323666&SM=1>

Aurobindo Pharma said that it received final approvals from US Food and Drug Administration for two Abbreviated New Drug Applications namely Ceftazidime for injection USP 500mg, 1g, and 2g per vial and Ceftazidime for injection USP 6g per vial strengths.

Ceftazidime for injection USP 500mg, 1g, and 2g per vial and Ceftazidime for injection USP 6g per vial are Sterile Cephalosporin product under the anti-infective segment and generic equivalent to GlaxoSmithKline's Reference Listed Drug Fortaz for Injections USP Ceftazidime for injection USP 500mg, 1g, and 2g per vial and Ceftazidime for injection USP 6g per vial.

Ceftazidime for injection is indicated for treatment of infections caused by susceptible gram negative bacilli, lower respiratory tract infection, abdominal cavity and biliary tract infection, complex urinary infections, serious skin soft tissue infections etc. The product has a market size of about \$30 million as per Newport data December 2009 and is ready for launch.